Thursday, October 15, 2026

Silver Futures Is 9% Down In The Last 10 Sessions

Silver Futures Is 9% Down In The Last 10 Sessions

(VIANEWS) - Silver (SI) has been up by 9.31% for the last 10 sessions. At 05:52 EST on Friday, 26 July, Silver (SI) is $27.92.

Volume

Today's last reported volume for Silver is 19154, 99.99% below its average volume of 9033228014.98.

Volatility

Silver's last week, last month's, and last quarter's current intraday variation average was 1.24%, 0.75%, and 1.40%, respectively.

Silver's highest amplitude of average volatility was 1.24% (last week), 1.17% (last month), and 1.40% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Silver's commodity is considered to be oversold (<=20).

Previous days news about Silver (SI)

  • Silver price forecast: xag/usd holds position above $29.00 ahead of US PMI data. According to FXStreet on Wednesday, 24 July, "The safe-haven assets like Silver could lose some demand from the increased optimism surrounding potential ceasefire negotiations between Israel and Hamas. "
  • Silver price analysis: break below key support is a bearish development. According to FXStreet on Thursday, 25 July, "The precious metal had been rising in what looked like a Measured Move (MM) pattern, with a C wave that extended substantially higher towards a target in the mid-$34s, however, after rallying up to a peak at $31.76, Silver capitulated and came tumbling down.", "The Relative Strength Index (RSI) momentum indicator is not yet oversold suggesting Silver has more scope to fall."

News about

  • According to FXStreet on Friday, 26 July, "The stronger-than-expected US Gross Domestic Product (GDP) print released on Thursday raised hopes for increasing demand in the world's largest fuel consumer and turned out to be a key factor acting as a tailwind for Crude Oil prices. ", "The crucial inflation data should influence the Fed's rate-cut path, which will drive the USD demand and determine the next leg of a directional move for Crude Oil prices, which, so far, has been showing some resilience below the key 200-day Simple Moving Average (SMA)."
  • According to FXStreet on Wednesday, 24 July, "On Tuesday, the American Petroleum Institute (API) reported a drop of 3.9 million barrels in Weekly Crude Oil Stock for the week ending July 19, exceeding market expectations of a 2.47 million-barrel decrease. ", "The US Energy Information Administration's (EIA) Crude Oil Stocks Change report, scheduled for Wednesday, is anticipated to show a 0.7 million-barrel increase for the same period."
  • According to FXStreet on Wednesday, 24 July, "On Tuesday, the American Petroleum Institute (API) reported a drop of 3.9 million barrels in Weekly Crude Oil Stock for the week ending July 19, exceeding market expectations of a 2.47 million-barrel decrease. ", "The US Energy Information Administration's (EIA) Crude Oil Stocks Change report, scheduled for Wednesday, is anticipated to show a 0.7 million-barrel increase for the same period."

More news about Silver (SI).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com